Liquidia (NASDAQ:LQDA) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Liquidia (NASDAQ:LQDA) in a research note issued to investors on Friday morning, Marketbeat.com reports. The brokerage issued an overweight rating and a $20.00 price objective on the stock.

Other analysts have also recently issued research reports about the stock. Lifesci Capital started coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. Scotiabank started coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price target on shares of Liquidia in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.60.

Liquidia Trading Up 4.8 %

Shares of LQDA stock opened at $11.10 on Friday. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.99. The firm has a fifty day simple moving average of $10.91 and a 200-day simple moving average of $11.18. The company has a market capitalization of $939.47 million, a PE ratio of -6.81 and a beta of 0.22.

Insider Activity

In related news, CEO Roger Jeffs sold 8,053 shares of the firm’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the sale, the chief executive officer now directly owns 812,193 shares of the company’s stock, valued at $9,023,464.23. This trade represents a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the sale, the insider now owns 207,383 shares in the company, valued at $2,304,025.13. This represents a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,007 shares of company stock valued at $245,780 over the last ninety days. 30.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

A number of hedge funds have recently added to or reduced their stakes in the stock. Whitcomb & Hess Inc. increased its position in Liquidia by 10.2% in the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after buying an additional 1,074 shares during the last quarter. Arizona State Retirement System grew its holdings in shares of Liquidia by 10.7% during the 2nd quarter. Arizona State Retirement System now owns 13,842 shares of the company’s stock valued at $166,000 after purchasing an additional 1,341 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of Liquidia during the second quarter valued at approximately $27,000. Profund Advisors LLC grew its stake in shares of Liquidia by 31.6% in the second quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock worth $173,000 after purchasing an additional 3,466 shares during the last quarter. Finally, DMC Group LLC lifted its position in shares of Liquidia by 36.7% in the 3rd quarter. DMC Group LLC now owns 13,883 shares of the company’s stock worth $139,000 after purchasing an additional 3,725 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).